CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that the U.S.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ), the Broad Institute of Harvard and MIT, and Medicines for Malaria Ventures (MMV) today announced that its scientists presented several posters, in addition to an oral presentation, this week at the American Society of Tropical Medicine and Hygiene (ASTMH) in New Orleans, La. The research focused on progress these organizations have made through their ongoing collaboration to develop improved treatment therapies for malaria.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the FDA’s Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 – 0) in favor of approval without conditions of Synvisc-One™ (hylan G-F 20).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today reported preliminary data on secondary endpoints from its CLASSIC II investigational study examining the safety and effectiveness of Clolar® (clofarabine) as a single agent to treat high-risk adult patients with acute myeloid leukemia (AML).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that its Premarket Approval (PMA) application supplement for Synvisc-One™ (hylan G-F 20) will be discussed this Tuesday, December 9th, at a public meeting of the FDA’s Orthopaedic and Rehabilitation Devices Advisory Committee in Gaithersburg, Maryland.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it has filed a supplemental New Drug Application with the U.S.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the FDA plans an Accelerated Approval for Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale for the treatment of Late Onset Pompe disease.
CAMBRIDGE, Mass. & COLUMBIA, Md.--(BUSINESS WIRE)--Genzyme Corp. (Nasdaq: GENZ) and Osiris Therapeutics (Nasdaq: OSIR) announced today that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to treat a wide range of diseases. These stem-cell products are designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation.